In vitro Soluble CD30 Levels in Patients with Chronic Stable Coronary Artery Disease
Abstract
The CD30 antigen seems to play a costimulatory role in maintaining the physiological balance between T-helper (Th)1/Th2 immune responses. In this study, plasma and in vitro soluble CD30 (sCD30) secretion was investigated in patients with coronary artery disease (CAD) as a plausible marker of dysregulated immune response.
Twenty one patients with angiographically confirmed CAD and 31 healthy controls took part in this study. The levels of the activation marker sCD30 were determined in plasma and phytohaemagglutinin (PHA)-stimulated and unstimulated peripheral blood mononuclear cell cultures by ELISA.
Plasma sCD30 levels did not differ significantly between the patients and controls. However, spontaneous sCD30 secretion was significantly lower in patients with CAD compared to controls (p < 0.001). The soluble CD30 levels were significantly increased in the supernatant of PHA-stimulated PBMCs compared to unstimulated cultures in both groups of patients and controls (p < 0.001). PHA-stimulated sCD30 secretion was found to be lower in patients compared to controls; however, the difference was not statistically significant.
Plasma sCD30 levels were not statistically different in patients with chronic stable CAD, a well-known Th1-mediated disease, compared to controls; whereas decreased spontaneous and PHA-stimulated sCD30 secretion in patients with CAD might indicate the progressive shift towards a Th1 immune response.
1. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352(16):1685-95.
2. Lundberg AM, Hansson GK. Innate immune signals in atherosclerosis. Clin Immunol 2010; 134(1):5-24.
3. Andersson J, Libby P, Hansson GK. Adaptive immunity and atherosclerosis. Clin Immunol 2010; 134(1):33-46.
4. Aukrust P, Otterdal K, Yndestad A, Sandberg WJ, Smith C, Ueland T, et al. The complex role of T-cell-based immunity in atherosclerosis. Curr Atheroscler Rep 2008;10(3):236-43.
5. Durkop H, Latza U, Hummel M, Eitelbach F, Seed B, Stein H. Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease. Cell 1992;68(3):421-7.
6. Schwab U, Stein H, Gerdes J, Lemke H, Kirchner H, Schaadt M, et al. Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin's disease and a subset of normal lymphoid cells. Nature 1982; 299(5878):65-7.
7. Tarkowski M. Expression and a role of CD30 in regulation of T-cell activity. Curr Opin Hematol 2003;10(4):267-71.
8. Del Prete G, De Carli M, Almerigogna F, Daniel CK, D'Elios MM, Zancuoghi G, et al. Preferential expression of CD30 by human CD4+ T cells producing Th2-type cytokines. FASEB J 1995; 9(1):81-6.
9. Manetti R, Annunziato F, Biagiotti R, Giudizi MG, Piccinni MP, Giannarini L, et al. CD30 expression by CD8+ T cells producing type 2 helper cytokines. Evidence for large numbers of CD8+CD30+ T cell clones in human immunodeficiency virus infection. J Exp Med 1994; 180(6):2407-11.
10. Hamann D, Hilkens CM, Grogan JL, Lens SM, Kapsenberg ML, Yazdanbakhsh M, et al. CD30 expression does not discriminate between human Th1- and Th2-type T cells. J Immunol 1996; 156(4):1387-91.
11. Bengtsson A, Johansson C, Linder MT, Hallden G, van der Ploeg I, Scheynius A. Not only Th2 cells but also Th1 and Th0 cells express CD30 after activation. J Leukoc Biol 1995; 58(6):683-9.
12. Opat S, Gaston JS. CD30:CD30 ligand interactions in the immune response. Autoimmunity 2000; 33(1):45-60.
13. Pellegrini P, Berghella AM, Contasta I, Adorno D. CD30 antigen: not a physiological marker for TH2 cells but an important costimulator molecule in the regulation of the balance between TH1/TH2 response. Transpl Immunol 2003; 12(1):49-61.
14. Pellegrini P, Totaro R, Contasta I, Berghella AM, Carolei A, Adorno D. CD30 antigen and multiple sclerosis: CD30, an important costimulatory molecule and marker of a regulatory subpopulation of dendritic cells, is involved in the maintenance of the physiological balance between TH1/TH2 immune responses and tolerance. The role of IFNbeta-1a in the treatment of multiple sclerosis. Neuroimmunomodulation 2005; 12(4):220-34.
15. Contasta I, Berghella AM, Pellegrini P, Adorno D.Passage from normal mucosa to adenoma and colon cancer: alteration of normal sCD30 mechanisms regulating TH1/TH2 cell functions. Cancer Biother Radiopharm 2003; 18(4):549-57.
16. Krampera M, Vinante F, Tavecchia L, Morosato L, Chilosi M, Romagnani S, et al. Progressive polarization towards a T helper/cytotoxic type-1 cytokine pattern during age-dependent maturation of the immune response inversely correlates with CD30 cell expression and serum concentration. Clin Exp Immunol 1999; 117(2):291-7.
17. Vinante F, Krampera M, Morosato L, Rigo A, Romagnani S, Pizzolo G. Peripheral T lymphocyte cytokine profile (IFNgamma, IL-2, IL-4) and CD30 expression/release during measles infection. Haematologica 1999; 84(8):683-9.
18. Romagnani S, Del Prete G, Maggi E, Chilosi M, Caligaris-Cappio F, Pizzolo G. CD30 and type 2 T helper (Th2) responses. J Leukoc Biol 1995; 57(5):726-30.
19. Horie R, Watanabe T. CD30: expression and function in health and disease. Semin Immunol 1998; 10(6):457-70.
20. D'Elios MM, Romagnani P, Scaletti C, Annunziato F, Manghetti M, Mavilia C, et al. In vivo CD30 expression in human diseases with predominant activation of Th2- like T cells. J Leukoc Biol 1997; 61(5):539-44.
21. Giacomelli R, Passacantando A, Parzanese I, Vernia P,Klidara N, Cucinelli F, et al. Serum levels of soluble CD30 are increased in ulcerative colitis (UC) but not in Crohn's disease (CD). Clin Exp Immunol 1998;111(3):532-5.
22. Munk ME, Kern P, Kaufmann SH. Human CD30+ cells are induced by Mycobacterium tuberculosis and present in tuberculosis lesions. Int Immunol 1997; 9(5):713-20.
23. Wang G, Hansen H, Tatsis E, Csernok E, Lemke H, Gross WL. High plasma levels of the soluble form of CD30 activation molecule reflect disease activity in patients with Wegener's granulomatosis. Am J Med 1997;102(6):517-23.
24. Okumura M, Hidaka Y, Kuroda S, Takeoka K, Tada H, Amino N. Increased serum concentration of soluble CD30 in patients with Graves' disease and Hashimoto's thyroiditis. J Clin Endocrinol Metab 1997; 82(6):1757-60.
25. Wakelkamp IM, Gerding MN, Van Der Meer JW, Prummel MF, Wiersinga WM. Both Th1- and Th2- derived cytokines in serum are elevated in Graves' ophthalmopathy. Clin Exp Immunol 2000; 121(3):453-7.
26. Krams SM, Cao S, Hayashi M, Villanueva JC, Martinez OM. Elevations in IFN-gamma, IL-5, and IL-10 in patients with the autoimmune disease primary biliary cirrhosis: association with autoantibodies and soluble CD30. Clin Immunol Immunopathol 1996; 80(3 Pt1):311-20.
27. Ichikawa Y, Yoshida M, Yamada C, Horiki T, Hoshina Y, Uchiyama M. Circulating soluble CD30 levels in primary Sjogren's syndrome, SLE and rheumatoid arthritis. Clin Exp Rheumatol 1998; 16(6):759-60.
28. Gerli R, Caligaris-Cappio F, Bistoni O, Bertero MT,Giacomelli R, Falini B. Soluble CD30 in primary Sjogren's syndrome. Clin Exp Rheumatol 1999;17(3):389-90.
29. Gerli R, Muscat C, Bistoni O, Falini B, Tomassini C, Agea E, et al. High levels of the soluble form of CD30 molecule in rheumatoid arthritis (RA) are expression of CD30+ T cell involvement in the inflamed joints. Clin Exp Immunol 1995; 102(3):547-50.
30. Gerli R, Pitzalis C, Bistoni O, Falini B, Costantini V, Russano A, et al. CD30+ T cells in rheumatoid synovitis: mechanisms of recruitment and functional role. J Immunol 2000; 164(8):4399-407.
31. Gerli R, Lunardi C, Vinante F, Bistoni O, Pizzolo G, Pitzalis C. Role of CD30+ T cells in rheumatoid arthritis: a counter-regulatory paradigm for Th1-driven diseases. Trends Immunol 2001; 22(2):72-7.
32. van Roon JA, van Roy JL, Duits A, Lafeber FP, Bijlsma JW. Proinflammatory cytokine production and cartilage damage due to rheumatoid synovial T helper-1 activation is inhibited by interleukin-4. Ann Rheum Dis 1995;54(10):836-40.
33. Walmsley M, Katsikis PD, Abney E, Parry S, Williams RO, Maini RN, et al. Interleukin-10 inhibition of the progression of established collagen-induced arthritis. Arthritis Rheum 1996; 39(3):495-503.
34. Joosten LA, Lubberts E, Durez P, Helsen MM, Jacobs MJ, Goldman M, et al. Role of interleukin-4 and interleukin-10 in murine collagen-induced arthritis. protective effect of interleukin-4 and interleukin-10 treatment on cartilage destruction. Arthritis Rheum 1997;40(2):249-60.
35. Gerli R, Bistoni O, Lunardi C, Giacomelli R, Tomassini C, Biagini P, et al. Soluble CD30 in early rheumatoid arthritis as a predictor of good response to second-line therapy. Rheumatology (Oxford) 1999; 38(12):1282-4.
36. Kurts C, Carbone FR, Krummel MF, Koch KM, Miller JF, Heath WR. Signalling through CD30 protects against autoimmune diabetes mediated by CD8 T cells. Nature1999; 398(6725):341-4.
37. Dai Z, Li Q, Wang Y, Gao G, Diggs LS, Tellides G, et al.CD4+CD25+ regulatory T cells suppress allograft rejection mediated by memory CD8+ T cells via a CD30- dependent mechanism. J Clin Invest 2004; 113(2):310-7.
38. Mandal K, Jahangiri M, Xu Q. Autoimmune mechanisms of atherosclerosis. Handb Exp Pharmacol 2005; (170):723-43.
39. Matsuura E, Kobayashi K, Matsunami Y, Shen L, Quan N, Makarova M, et al. Autoimmunity, infectious immunity, and atherosclerosis. J Clin Immunol 2009; 29(6):714-21.
40. Del Prete G, De Carli M, D'Elios MM, Daniel KC, Almerigogna F, Alderson M, et al. CD30-mediated signaling promotes the development of human T helper type 2-like T cells. J Exp Med 1995; 182(6):1655-61.
| Files | ||
| Issue | Vol 10, No 4 (2011) | |
| Section | Articles | |
| Keywords | ||
| Coronary artery disease Soluble CD30 T-helper | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
